The significant increase in sensitivity of ALL cells to PARP1/2 inhibitors relative to non-cancer cells indicates that this may be a potential pan-ALL therapeutic target that was discovered through protein abundance analysis. Here, PARP1 is linked to acute lymphoblastic leukemia.